AVCT near 52-week high as Avacta doses first patient in AVA6103 Phase 1 trial

Avacta Group PLC (AIM: AVCT), the London-headquartered clinical-stage biopharmaceutical company, announced on 31 March 2026 that the first patient has been dosed in the FOCUS-01 trial, a multicenter Phase 1 study evaluating FAP-Exd (AVA6103), its second clinical candidate and the first asset built on the company’s next-generation pre|CISION sustained-release delivery mechanism. The milestone, achieved across three specialist United States oncology centers simultaneously, marks the opening of Avacta’s second active clinical program and validates progress in developing the Gen Two iteration of its tumor-activated peptide drug conjugate platform. The announcement follows an oversubscribed £10 million equity raise completed just days earlier, providing Avacta with a cash runway into early Q1 2027 and beyond the initial data readout expected from FOCUS-01 later this year. For a company whose near-term investment case rests entirely on clinical execution and platform validation, the timing of this patient dosing alongside secured financing is a meaningful confluence of operational and capital milestones.

What is AVA6103 and how does it differ from Avacta’s first clinical candidate, faridoxorubicin?

To understand why AVA6103 matters strategically, it helps to situate it relative to faridoxorubicin (AVA6000), Avacta’s first-generation pre|CISION asset. Both compounds share the same platform logic: a peptide sequence that is selectively cleaved by Fibroblast Activation Protein, or FAP, a protease that is highly expressed in the tumor microenvironment but largely absent in healthy tissue. The FAP specificity is what enables the pre|CISION platform to concentrate cytotoxic payloads within tumors while limiting the systemic toxicity that has historically constrained dosing of potent chemotherapeutic agents.

AVA6000 is a Gen One construct, linking doxorubicin to the FAP-targeting peptide through a relatively direct chemical bond. AVA6103 is classified as Gen Two because the chemistry governing payload release has been redesigned to provide sustained, prolonged release of the active molecule within the tumor, rather than a single bolus release event. The practical implication is that intratumoral drug exposure is extended and systemic spillover is further reduced. Avacta is pairing this refined release mechanism with exatecan, a potent topoisomerase I inhibitor that has become one of the most commercially validated payloads in the broader antibody drug conjugate space following its use in Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan franchise.

The combination of an improved delivery mechanism and a high-potency, commercially established payload explains why Avacta has been signalling AVA6103 as an asset it intends to retain full rights to at least through the initial Phase 1a data readout. The company wants to establish proof-of-concept in humans before entering partnership discussions, which is a credible but capital-intensive strategy that makes the recently closed equity raise structurally important rather than routine.

How did AI-guided tumor selection shape the FOCUS-01 trial design and what does that signal about Avacta’s data strategy?

The FOCUS-01 protocol discloses a notable methodological choice. Rather than selecting initial tumor indications based solely on FAP expression or clinical convention, Avacta used an artificial intelligence approach developed through its collaboration with Tempus AI to identify cancer types where co-expression of FAP and SLFN11 is highest. SLFN11 is a gene whose expression is associated with sensitivity to topoisomerase I inhibitors. The rationale is that patients whose tumors express both FAP (the target for drug delivery) and SLFN11 (a marker of sensitivity to the exatecan payload) represent the population most likely to respond.

This is a meaningful step beyond simple biomarker selection. By layering two predictive markers rather than one, Avacta is attempting to optimize the probability of observing signal in a small Phase 1 cohort. The four tumor types selected for the dose escalation phase are pancreatic cancer, cervical and vulvar cancer, gastric and gastroesophageal junction cancer, and small cell lung cancer. These represent difficult-to-treat indications where existing therapies leave significant unmet need, and where topoisomerase I inhibitor activity has shown varying degrees of biological relevance.

The trial is designed to enroll approximately 144 patients across dose escalation and expansion phases, using a Bayesian Optimal Interval methodology that runs two dosing arms in parallel, an every-three-weeks schedule and an every-two-weeks schedule. This design structure is intended to accelerate cohort management and minimize the statistical risk of dose misjudgment, which is particularly important for an early-phase oncology trial where safety and pharmacokinetic characterization are the primary objectives.

Which US oncology centers are enrolling patients and what does the site selection tell investors about clinical execution capacity?

The three centers open for enrollment at launch are the Virginia Cancer Specialists Research Institute in Fairfax, Virginia, NEXT Oncology Specialists in Dallas, Texas, and START Midwest Center for Oncology Research in Grand Rapids, Michigan. These are not general academic medical centers. They are specialist oncology research institutions with established track records in early-phase trials and patient throughput. Simultaneous opening across three geographically distributed sites reduces single-center dependency and accelerates enrollment velocity, which is operationally significant for a company managing its cash runway against a defined data readout timeline.

The choice of US sites rather than UK or European sites for the initial opening also reflects practical realities. Specialist early-phase oncology infrastructure in the United States, particularly within networks like NEXT Oncology and START, provides access to large patient pools in the relevant tumor types and experienced principal investigators. Alexander Spira, co-director of the Virginia Cancer Specialists Research Institute and a lead investigator on FOCUS-01, has noted the potential of targeting a topoisomerase I inhibitor specifically to the tumor while minimizing damage to healthy tissue.

What is the strategic significance of the £10 million fundraise and how does the dilution calculus look for existing shareholders?

The equity raise announced on 26 March and confirmed as oversubscribed on 27 March 2026 issued approximately 15.87 million new shares at 63 pence each, representing a discount of roughly 9.35% to the closing mid-market price of 69.5 pence on the day prior to announcement. Total dilution is approximately 3.6% of the pre-raise issued share capital, which places the enlarged share count at 456,288,511 shares. Two non-executive directors participated in the subscription for a combined £550,000, and Zeus Capital, acting as sole bookrunner, subscribed for £200,000, triggering its previously agreed warrant entitlement over approximately 4.36 million shares exercisable at 63 pence for five years.

The net proceeds are expected to extend the company’s cash runway into early Q1 2027. Critically, Avacta has structured this runway to sit beyond the expected initial FOCUS-01 data readout, which the company has indicated should arrive in the second half of 2026. This is deliberate. A clinical-stage company that runs out of cash before its pivotal data readout is effectively negotiating from a position of weakness in any partnership discussion. By closing the raise before patient dosing commenced, Avacta has decoupled its financing position from near-term clinical uncertainty.

The raise also coincides with Phase 1b expansion cohort activity in AVA6000, where enrollment is nearly complete across salivary gland cancer, triple negative breast cancer, and soft tissue sarcoma. Additional efficacy and cardiac safety data from AVA6000’s Phase 1b cohorts are expected in the first half of 2026. Avacta has described these data as likely to solidify the case for faridoxorubicin’s commercial value, which implies the company is building toward a partnering event for AVA6000 in parallel with AVA6103’s clinical development.

How does the AVCT stock price and market positioning reflect the risk profile of a dual-asset clinical-stage company in 2026?

Avacta Group shares were trading around 69 pence in late March 2026, broadly in line with the placing price of 63 pence. The 52-week range spans from 26 pence to 84 pence, reflecting the binary volatility that characterizes AIM-listed clinical-stage biotechnology companies. The stock has substantially outperformed the FTSE All-Share Index over the prior six months, with a gain of more than 24%, suggesting that sentiment has been constructive ahead of the dual catalysts of the AVA6000 data readout and the AVA6103 trial opening. Market capitalization at these levels sits around £305 million.

The consensus analyst price target reported by coverage services stands around 83 pence, implying upside of approximately 20% from recent levels, with buy recommendations from the analysts covering the stock. That said, Avacta carries no revenue from therapeutic products, reports operating losses, and its balance sheet position after the raise is funded only through early 2027. The investment case is consequently a high-conviction, high-risk wager on two clinical readouts arriving on schedule and delivering interpretable positive signal. Investors pricing the stock anywhere above 60 to 70 pence are effectively capitalizing the pipeline at multiples that assume some probability of clinical and commercial success, rather than terminal value of existing assets.

The oversubscription of the placing is a soft signal of institutional confidence in the near-term story, though it should be noted that a 9.35% discount is not an unusual hurdle to clear for an AIM biotech. Director participation is marginally more meaningful as a signal of insider conviction. The issuance of warrants to Zeus Capital is consistent with established broker arrangements and does not alter the fundamental risk picture materially.

Where does AVA6103 sit in the broader peptide drug conjugate and XDC landscape and what are the competitive risks?

Peptide drug conjugates, or PDCs, occupy a contested adjacent position to antibody drug conjugates in the cancer drug delivery space. Where ADCs use antibodies as targeting vehicles, PDCs use shorter peptide sequences, which offer potential advantages in tissue penetration, manufacturing scalability, and cost, but have generally lagged ADCs in clinical validation. The commercial success of trastuzumab deruxtecan and other ADC platforms has attracted enormous capital into the broader XDC category, which is how Avacta classifies its pre|CISION constructs.

Avacta’s differentiation claim rests on FAP as the targeting mechanism. FAP is expressed across approximately 90% of solid tumors, according to the company’s own preclinical data, which theoretically gives the pre|CISION platform broader applicability than antibody-based delivery approaches targeting individual tumor antigens. The Gen Two sustained-release mechanism addresses a specific limitation of first-generation constructs, where peak systemic drug exposure around dosing events can cause off-tumor toxicity. If the pharmacokinetic data from FOCUS-01 bears out the preclinical profile, demonstrating high intratumoral drug concentration with low systemic exposure, it would represent a meaningful clinical differentiation point.

However, competition in this space is escalating. Multiple companies are pursuing FAP-targeted therapies including radioligand approaches, bispecific antibodies, and other small molecule delivery formats. The topoisomerase I inhibitor payload has already been extensively explored in ADC formats, and any comparison of AVA6103’s clinical data with the ADC reference class will be rigorous. Avacta is not competing in a vacuum and its initial Phase 1a data will be scrutinized against the broader XDC and ADC literature rather than evaluated in isolation.

What are the key execution risks between now and the AVA6103 initial data readout expected in late 2026?

The risks between patient dosing and data readout are common to any early-phase oncology trial but are worth framing clearly. Enrollment pace is the first variable. A 144-patient trial across four tumor types and two dosing arms requires consistent patient flow from the initial three centers plus any additional sites that open over the enrollment period. Delays in enrollment shift the data readout timeline, which directly affects the company’s cash dynamics.

Dose escalation safety decisions are the second variable. The Phase 1a portion of FOCUS-01 will generate safety and pharmacokinetic data at each dose level before advancing to higher doses. Unexpected toxicity findings, even if manageable, can slow the protocol and delay the clarity of the pharmacokinetic profile that the company needs to demonstrate platform differentiation. Given that AVA6000’s development has included modifications to dosing caps related to cardiac safety findings, investors have historical context for how clinical adjustments can reshape expectations.

Third, the interpretation of preliminary efficacy signals in a Phase 1 setting is inherently limited. Tumor response observations in a dose escalation study are hypothesis-generating rather than confirmatory. The initial data readout will likely be positioned primarily as a safety, pharmacokinetic, and pharmacodynamic result with any early efficacy observations presented as supportive context. Managing the communication of those data to a market that has priced in some probability of success will require careful framing.

Key takeaways: What Avacta’s FOCUS-01 patient dosing means for the company, pipeline, and sector

• Avacta has opened its second active clinical program with the dosing of the first patient in the FOCUS-01 Phase 1 trial of AVA6103, marking the entry of the Gen Two pre|CISION sustained-release mechanism into human testing.
• AVA6103 uses exatecan, a commercially validated topoisomerase I inhibitor payload, delivered via a FAP-targeting peptide with a sustained-release mechanism designed to maximize intratumoral drug exposure and minimize systemic toxicity.
• AI-guided co-expression analysis of FAP and SLFN11 across tumor types shaped the selection of four initial cancer indications: pancreatic, cervical and vulvar, gastric and gastroesophageal junction, and small cell lung cancer.
• Simultaneous enrollment opening at three specialist US oncology research institutions signals execution readiness and should support enrollment velocity relative to a single-site launch.
• The £10 million oversubscribed placing, completed days before the first patient dosing, extends the cash runway into early Q1 2027 and beyond the initial data readout expected in the second half of 2026, reducing financing risk during the critical clinical window.
• Dilution from the raise is modest at approximately 3.6% of pre-raise share capital, and director participation in the subscription provides a soft signal of internal conviction.
• AVCT shares trade near 69 pence, well above the 52-week low of 26 pence, with a 52-week high of 84 pence and a consensus analyst target of approximately 83 pence, reflecting market pricing that captures meaningful pipeline probability premium.
• AVA6000 Phase 1b data across salivary gland cancer, triple negative breast cancer, and soft tissue sarcoma remain a near-term catalyst in the first half of 2026 and are expected to inform partnering discussions for the lead asset.
• The broader competitive landscape for FAP-targeted and PDC-based oncology delivery is intensifying, meaning AVA6103’s Phase 1 data will be benchmarked against an increasingly sophisticated peer set including established ADC platforms.
• The investment case remains binary and execution-dependent: clinical and financial upside is substantial if FOCUS-01 delivers interpretable pharmacokinetic differentiation, while the absence of product revenue and a defined funding horizon mean any clinical setback has asymmetric downside for the share price.